Showing 1851-1860 of 3121 results for "".
The Price of a Penalty: Unraveling CMS's Latest Moves
https://practicaldermatology.com/topics/practice-management/the-price-of-a-penalty-unraveling-cmss-latest-moves/21435/State Legislation of EHRs: A Sweeping Precedent?
https://practicaldermatology.com/topics/practice-management/state-ehr-legislation-a-new-precedent/21483/A new law in Massachusetts requires all licensed physicians to be using an EHR by 2015.Analyzing the New Consensus Statement on Immunotherapy for Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-the-new-consensus-statement-on-immunotherapy-for-melanoma/21506/In-Review: Two New Melanoma Agents Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/in-review-two-new-melanoma-agents-approved/21534/Utilizing genetic abnormalities, new therapies are carving out new possibilities for melanoma treatment.Financial Benchmarking Update for Dermatology Practices
https://practicaldermatology.com/topics/practice-management/financial-benchmarking-update-for-dermatology-practices/21621/Successful practices use benchmarking to compare their performance to others, assess their own performance over time, and plan for the long term.Dermatology Q&A: Treating Melasma and Photoaging Without Hydroquinone
https://practicaldermatology.com/topics/general-topics/dermatology-qa-treating-melasma-and-photoaging-without-hydroquinone/21867/A recently unveiled skin brightening cream may signal a new direction in the treatment and prevention of pigmentation disorders.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuBiologics and Beyond
https://practicaldermatology.com/topics/psoriasis/biologics-and-beyond/23554/A look at off-label use of biologics and JAK inhibitors.